Karuna Therapeutics Inc. (KRTX) Misses Q3 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates
November 3, 2022 6:30 AM EDTInitiated the Phase 3 ADEPT-1 trial of KarXT in Alzheimers disease psychosis in the third quarter of 2022
Phase 3 EMERGENT-3 trial completed enrollment in the fourth quarter of 2022, with topline data anticipated in the first quarter of 2023
On track to submit New Drug Application (NDA) for KarXT in schizophrenia with the U.S. Food & Drug Administration (FDA) in mid-2023
$1.2 billion in cash is expected to fund operations through the end of 2025
BOSTON--(BUSINESS WIRE)-- Karuna Therapeutics, Inc. (NASDAQ:... More
